ABT - Abbott Laboratories

NYSE - Nasdaq Real Time Price. Currency in USD
63.55
+0.12 (+0.19%)
As of 9:42AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close63.43
Open63.45
Bid62.50 x 800
Ask63.99 x 3100
Day's Range63.45 - 63.67
52 Week Range48.58 - 65.90
Volume97,035
Avg. Volume4,993,750
Market Cap111.487B
Beta1.75
PE Ratio (TTM)121.74
EPS (TTM)0.52
Earnings DateOct 16, 2018 - Oct 22, 2018
Forward Dividend & Yield1.12 (1.73%)
Ex-Dividend Date2018-07-12
1y Target Est71.00
Trade prices are not sourced from all markets
  • What to Expect for Boston Scientific in Fiscal 2018
    Market Realist7 days ago

    What to Expect for Boston Scientific in Fiscal 2018

    During its Q2 2018 earnings release on July 25, Boston Scientific (BSX) updated its fiscal 2018 guidance. The company raised its fiscal 2018 sales guidance and maintained its adjusted EPS guidance at $1.37–$1.41, representing growth of 9%–12%.

  • What Analysts Expect from Haemonetics in Q1 2019
    Market Realist8 days ago

    What Analysts Expect from Haemonetics in Q1 2019

    Haemonetics (HAE) is a leading healthcare company in blood management solutions. Its devices portfolio includes surgical and diagnostic devices as well as blood and plasma center devices. The software portfolio includes blood center software, plasma center software, and hospital software.

  • Hologic Expects Robust Earnings Growth for Fiscal 2018
    Market Realist8 days ago

    Hologic Expects Robust Earnings Growth for Fiscal 2018

    In its fiscal third-quarter conference call, Hologic (HOLX) narrowed the projected range of its fiscal 2018 EPS from $2.22–$2.27 to $2.24–$2.26. Considering the midpoint of the updated EPS guidance range, the company expects YoY (year-over-year) EPS growth of ~10.8% for fiscal 2018. 

  • Hologic Raised Its Revenue Guidance for Fiscal 2018
    Market Realist11 days ago

    Hologic Raised Its Revenue Guidance for Fiscal 2018

    During its fiscal third quarter conference call, Hologic (HOLX) raised its fiscal 2018 non-GAAP revenue guidance from $3.18 billion–$3.21 billion to ~$3.21 billion–$3.22 billion. So, its YoY (year-over-year) reported revenue growth rate for fiscal 2018 is expected to be 4.8%–5.3%, higher than the previously projected range of 4.0%–4.9%. 

  • Analysts’ Recommendations for Hologic and Its Peers in August
    Market Realist11 days ago

    Analysts’ Recommendations for Hologic and Its Peers in August

    In the fiscal third quarter, Hologic reported non-GAAP EPS of ~$0.58, which was a YoY rise of 16.0%. Hologic surpassed its revenue and EPS guidance for the fiscal third quarter. Hologic’s Diagnostics business posted a recovery compared to the fiscal second quarter, and its Surgical business has posted gradual improvement since the fiscal first quarter.

  • Boston Scientific’s Q2 2018 Adjusted EPS Exceed Guidance
    Market Realist11 days ago

    Boston Scientific’s Q2 2018 Adjusted EPS Exceed Guidance

    In the second quarter, Boston Scientific’s adjusted EPS grew 28% YoY (year-over-year) to $0.41, exceeding its guidance of $0.33–$0.35. Boston Scientific’s strong earnings growth in the quarter was due to its strong profit and loss metrics. The company is working on improving cost efficiencies through its end-to-end business by streamlining and automation initiatives, expanding global shared services, and leveraging global sourcing teams. Peers Abbott Laboratories (ABT), Edwards Lifesciences (EW), and Thermo Fisher Scientific (TMO) reported adjusted EPS growth of 17.7%, 30.5%, and 19. ...

  • Can Boston Scientific Maintain Its Strong Sales Momentum?
    Market Realist11 days ago

    Can Boston Scientific Maintain Its Strong Sales Momentum?

    On July 25, Boston Scientific (BSX) released its Q2 2018 earnings results. It reported revenue of $2.49 billion, exceeding Wall Street’s estimate of ~$2.46 billion and coming in at the higher end of the company’s $2.45 billion–$2.5 billion guidance.

  • What Analysts Recommend for Boston Scientific, Post-Q2 Results
    Market Realist11 days ago

    What Analysts Recommend for Boston Scientific, Post-Q2 Results

    Boston Scientific (BSX) announced its Q2 2018 results on July 25, exceeding analysts’ estimates. That day, BSX stock rose ~2.2%, while the iShares US Medical Devices ETF (IHI) rose ~1.4%. BSX comprises ~4.7% of IHI.

  • Abbott Expands its Directional Deep Brain Stimulation Therapy by Offering New MR-Conditional Labeling
    PR Newswire12 days ago

    Abbott Expands its Directional Deep Brain Stimulation Therapy by Offering New MR-Conditional Labeling

    - FDA approval of new software upgrade for Abbott's deep brain stimulation therapy enables advanced, patient-centric features for people living with Parkinson's disease and essential tremor - New Informity™ ...

  • What DexCom Just Said About Its Future
    Motley Fool12 days ago

    What DexCom Just Said About Its Future

    Sales momentum for the maker of continuous monitors for diabetes patients could accelerate.

  • Trending: Automakers Breathe Sigh of Relief over U.S.-EU Trade Ceasefire
    ETF Database12 days ago

    Trending: Automakers Breathe Sigh of Relief over U.S.-EU Trade Ceasefire

    Shares of automotive companies climbed last Thursday as U.S. President Donald Trump eased the car tariff threat following a meeting with European Commission President Jean-Claude Juncker.

  • Abbott Laboratories’ Stock Price Performance in July
    Market Realist13 days ago

    Abbott Laboratories’ Stock Price Performance in July

    On July 24, Abbott Laboratories (ABT) ended the trading day at $64.40 per share. Currently, the stock is trading higher than its 50-day moving average of $62.45 and its 200-day moving average of $60.75.

  • What to Expect from Abbott Laboratories in Fiscal 2018
    Market Realist13 days ago

    What to Expect from Abbott Laboratories in Fiscal 2018

    During Abbott Laboratories’ (ABT) second-quarter earnings release on July 18, the company increased its fiscal 2018 guidance. This move was triggered by the company’s strong performance in the quarter. ABT stock rose ~3.1% on the day of its earnings announcement.

  • Analysts’ Recommendations for DaVita
    Market Realist14 days ago

    Analysts’ Recommendations for DaVita

    As discussed previously, analysts expect DaVita (DVA) to post revenue of $2.877 billion, adjusted net income of ~$175.97 million, and non-GAAP EPS of ~$0.97 in Q2 2018. Of the ten analysts tracking DaVita, five recommend “strong buy,” four recommend “hold,” and one recommends “sell.” 

  • How the Freestyle Libre CGM Opportunity Is Playing Out for ABT
    Market Realist14 days ago

    How the Freestyle Libre CGM Opportunity Is Playing Out for ABT

    Abbott Laboratories’ (ABT) Diabetes segment registered second-quarter sales growth of ~40.0%, reaching $470.0 million. The Diabetes segment’s strong performance was driven by the continued uptake of Abbott’s Freestyle Libre CGM (continuous glucose monitoring) device. The device was approved by the FDA in September 2017. Abbott Laboratories gained market share in the second quarter in the diabetes market space from competitors such as Medtronic (MDT) and Dexcom (DXCM) due to the strong momentum in its Freestyle Libre adoption.

  • What Subdued ABT’s Medical Devices Segment in Q2 2018?
    Market Realist14 days ago

    What Subdued ABT’s Medical Devices Segment in Q2 2018?

    Q2 Results: What Drove Its Robust Growth? Abbott Laboratories (ABT) reported robust second-quarter revenues in its Medical Devices segment, as we discussed in the previous article. ABT’s heart failure and neuromodulation sales rose ~1.0%, and ~5.8%, respectively, in the second quarter on an organic basis.

  • The Major Growth Drivers for ABT’s Medical Devices Business
    Market Realist14 days ago

    The Major Growth Drivers for ABT’s Medical Devices Business

    Q2 Results: What Drove Its Robust Growth? The Medical Devices segment’s sales registered YoY (year-over-year) growth of ~11.3% on a reported basis. On an organic basis, the segment’s sales were up ~8.2%.

  • TheStreet.com14 days ago

    Sector Rotation Is Powerful: This Tech Hit Is a Great Trade

    Over the last few days, we have heard and seen all sorts of creative investment basket acronyms in the tech sector from FAANG to FAANGMA, or the new AGMA (ok, I just made that one up). It does not change the fact that everyone and their mom was invested in the tech sector, given its phenomenal growth of around 30% in large-cap companies of about $100 billion or larger. Netflix dropped 15% on weak subscriber numbers.

  • Abbott Laboratories’ Nutrition Sales Recovered in Q2 2018
    Market Realist15 days ago

    Abbott Laboratories’ Nutrition Sales Recovered in Q2 2018

    In the second quarter, Abbott Laboratories (ABT) reported sales of $1.9 billion in its Nutrition business, which contributed ~24.0% to the company’s total sales of $7.8 billion in the quarter. The Nutrition segment’s sales registered YoY (year-over-year) growth of ~7.3% on a reported basis. In the second quarter, Abbott Laboratories’ international nutrition sales came in at $1.1 billion, up ~12.5% on a YoY basis.

  • ABT Saw 12.3% Growth in Established Pharmaceuticals Segment
    Market Realist15 days ago

    ABT Saw 12.3% Growth in Established Pharmaceuticals Segment

    Q2 Results: What Drove Its Robust Growth? The Established Pharmaceuticals segment sales registered YoY (year-over-year) growth of ~10.5% on a reported basis. Foreign exchange had a negative impact of ~1.8% on the business.

  • How ABT’s Diagnostics Business Performed in Q2 2018
    Market Realist15 days ago

    How ABT’s Diagnostics Business Performed in Q2 2018

    In the second quarter, Abbott Laboratories (ABT) reported sales of $1.9 billion in its Diagnostics business, which contributed ~24.0% to the company’s total sales of $7.8 billion in the quarter. The Diagnostic segment’s sales registered YoY (year-over-year) growth of ~47.2% on a reported basis. On an organic basis, the segment’s sales were up ~6.6%.

  • Wichita hospital selected for medical device clinical trial
    American City Business Journals18 days ago

    Wichita hospital selected for medical device clinical trial

    This places Via Christi — and Wichita for that matter — on the leading edge of a technology that eventually could be taken to market and possibly become a standard of care in cardiology.

  • Abbott's FreeStyle® Libre 14 Day Flash Glucose Monitoring System Now Approved in U.S.
    PR Newswire18 days ago

    Abbott's FreeStyle® Libre 14 Day Flash Glucose Monitoring System Now Approved in U.S.

    ABBOTT PARK, Ill., July 27, 2018 /PRNewswire/ -- Abbott (ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the FreeStyle® Libre 14 day Flash Glucose Monitoring system, which allows people with diabetes to wear the sensor up to 14 days with high accuracy. "At Abbott, we are continuously pushing for new innovations that minimize the daily burden of managing diabetes," said Jared Watkin, senior vice president, Diabetes Care, Abbott.